• Guided CVS Health to antitrust approval for its $70 billion acquisition of Aetna, the largest healthcare services deal ever and the largest announced deal of 2017.
    • Advised a leading U.S. airline in regulatory proceedings before DOT and foreign competition authorities in connection with applications for antitrust immunity for joint business agreements with international partners.
    • Advised a medical device manufacturer in its acquisition by a competitor, avoiding an FTC second request in the process.
    • Represented a financial services company in an FTC consumer protection matter, convincing the agency to close its investigation.
    • Represented a consumer goods company in an FTC investigation into its U.S.-origin marketing claims, obtaining a closing letter from the agency.
    • Represented Procter & Gamble in its acquisition of Gillette.
    • Represented R.J. Reynolds in its acquisition of Brown & Williamson.
    • Represented Roadway Express in its acquisition of Yellow Transit.
    • Represented DIRECTV in its acquisiton by News Corp.
    • Represented Ultramar Diamond Shamrock in its acquisition by Valero Energy.
    • Represented Bayer in In re Ciprofloxacin Hydrochloride Antitrust Litigation, involving antitrust claims arising from the settlement of pharmaceutical patent litigation.

    Includes matters handled at Dechert or prior to joining the firm.

    • Clash of the Global Titans: Privacy v. Competition — ABA Antitrust Law Section Spring Meeting, Washington, DC (April 2022)
    • Navigating Recent Developments in Global Merger Enforcement — Dechert Webinar (October 2020)
    • Should Antitrust Tame the Global Tech Giants? — ABA Section of Antitrust Law Spring Meeting, Washington, DC (April 2019) 
    • State Boards and Professional Licensing Post-NC Dental — American Health Lawyers Association/ABA Section of Antitrust Law Antitrust in Health Care Conference, Arlington, VA (May 2018)
    • Whose Internet Is It Anyway? — ABA Section of Antitrust Law Spring Meeting, Washington, DC (March 2018)
    • Noerr-Pennington and the FTC — ABA Section of Antitrust Law Exemptions & Immunities Committee Program, Washington, DC (January 2018)
    • The FTC’s New Section 5 Policy Statement: A Step Forward? — ABA Section of Antitrust Law Unilateral Conduct Committee Program, Washington, DC (September 2015)
    • Reflections on the Supreme Court’s North Carolina Dental Decision — Citizen Advocacy Center Event, Washington, DC (June 2015)
    • Fundamentals of Antitrust Exemptions and Immunities — ABA Section of Antitrust Law Exemptions & Immunities Committee Program, Washington, DC (May 2014)
    • Healthcare Antitrust: Physician Contracting and Joint Ventures — 2013 Southeast Healthcare Provider Conference, Charlotte, NC (September 2013)
    • Insurance and Other New Antitrust Targets: The Politics and Legislative Process of Antitrust Exemptions and Immunities — ABA Section of Antitrust Law Spring Meeting, Washington, DC (April 2010)
    • Does Telecom Have a Future? — Supernova 2008: Challenges for the Network Age, San Francisco, CA (June 2008)
    • Net Neutrality and the Future of the Internet — ABA Annual Meeting, San Francisco, CA (August 2007)

     

    • ABA Section of Antitrust Law
      • Co-Chair, Committee Operations (2022-present)
      • Vice-Chair, U.S. Comments & Policy Committee (2021-2022)     
      • Editorial Board Member, Antitrust Law Developments 9 (2020-2022)
      • Member, Long Range Planning Committee (2020-2021)
      • Co-Chair, Media & Technology Committee (2015 – 2020)
      • Chair, Exemptions & Immunities Committee (2013-2015)
      • Vice-Chair, Exemptions & Immunities Committee (2007-2012)
      • Vice-Chair, Programs Committee (2004-2007)
      • Member, Editorial Board, Annual Review of Antitrust Law Developments (2002-2004)